Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.67 |
| ▸ | CHEK1 | O14757 | 6/20 | 0.52 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5078006 | 0.90 | KDR (0.66) | KDRCHEK1TPSAB1HRH4F7 | |
| SCHEMBL5079412 | 0.87 | KDR (0.63) | KDRCHEK1TPSAB1F7 | |
| SCHEMBL144414 | 0.82 | KDR (0.61) | KDRCHEK1HRH4 | |
| SCHEMBL7252783 | 0.82 | KDR (0.62) | KDRCHEK1 | |
| SCHEMBL5078878 | 0.80 | KDR (1.00) | KDRCHEK1HRH4 | |
| SCHEMBL6864116 | 0.80 | CHEK1 (0.55) | KDRCHEK1 | |
| SCHEMBL5079415 | 0.79 | KDR (0.53) | KDRCHEK1MEN1KMT2AF7 | |
| SCHEMBL5076136 | 0.79 | KDR (0.53) | KDRCHEK1MEN1KMT2A | |
| SCHEMBL5076112 | 0.78 | CHEK1 (0.71) | KDRCHEK1 | |
| SCHEMBL5078783 | 0.77 | KDR (0.57) | KDRCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080274107-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-11-06 | — | — | US | disclosed |
| US-20080274107-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-11-06 | — | — | US | disclosed |
| US-20080274107-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-11-06 | — | — | US | disclosed |
| US-7186723-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186723-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050096344-A1 | Tyrosine kinase inhibitors | FRALEY MARK E (US) | 2005-05-05 | — | — | US | disclosed |
| US-6794393-B1 | inhibitors of VEGF; angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases; 1H-indole compounds having a fused nitrogen heterocycle amide in the 2-position | MERCK & CO., INC. | 2004-09-21 | — | — | US | disclosed |
| US-6306874-B1 | ENZYME INHIBITORS SUCH AS ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES, AND THE LIKE IN MAMMALS. | MERCK & CO., INC. | 2001-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096344-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885CHEK1 499/4885TPSAB1 2718/4885 |
| US-20080274107-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885CHEK1 499/4885TPSAB1 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.